News & Press Releases
Filter by:
Fundraising Woes Knock GPs off the Grid – What Next?
November 3, 2025
Investment Funds Practice Chair Kari Harris was quoted in a Buyouts article about how private equity firms are increasingly turning to alternative sources of capital amid a slowdown in traditional fundraising. One strategy gaining traction is the recycling of proceeds from asset sales into new investments, which many funds have become more flexible with.
Why 401(k) Plans Avoid Risk Capacity Details You Already Know
October 31, 2025
Forbes featured insights from Of Counsel Michelle Capezza in an article about the distinction between risk capacity and risk tolerance in retirement planning. The article notes that while many retirement plan participants intuitively understand the concept of risk capacity, its nuances are not always reflected in 401(k) plans.
FERC Decision Highlights Jurisdictional Limits on Large Load Tariffs
October 31, 2025
DOE Pushes FERC to Accelerate Data Center Interconnections
October 31, 2025
Intellectual Property Ownership Conundrums in Business Transactions
October 24, 2025
Business Law Today highlighted comments from Privacy & Cybersecurity Practice Co-chair Scott Lashway, who spoke on a panel at the American Bar Association Business Law Fall Meeting in September. Discussing the role of intellectual property in business transactions, the panel addressed important considerations for the various types of IP, distinguishing the less concrete “lowercase ip” from the more formalized “uppercase IP.”
Mintz advised the underwriters in connection with a $603 million public offering by Praxis Precision Medicines of 3,527,072 shares of common stock (which includes 501,592 shares of common stock issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock) at a public offering price of $157.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 318,470 shares of common stock at the public offering price per share less the $0.0001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds to Praxis Precision Medicines from this offering were approximately $603 million before deducting underwriting discounts and commissions and other offering expenses.
